Inclusion Criteria <br/ >For inclusion in the study patients should fulfill the following criteria based on local regulations <br/ >1 Provision of informed consent prior to any study-specific procedures <br/ >2 Male or female patients aged 18 years on the day consent given <br/ >3 Currently hospitalized <br/ >4 Hospital admission no more than 4 days prior to screening <br/ >5 Confirmed SARS-CoV-2 infection by laboratory testing within 10 days prior to screening, or strongly suspected SARS-CoV-2 infection on presentation <br/ >6 Chest radiography or CT findings that, in the opinion of the investigator are consistent with COVID-19 <br/ >7 Mild-moderate disease SpO2 94 with low-flow supplemental oxygen (5 liters or less) <br/ >8 Medical history of at least one of the following <br/ >(a) hypertension <br/ >(b) T2DM <br/ >(c) atherosclerotic cardiovascular disease <br/ >(d) heart failure (with either reduced or preserved LVEF) <br/ >(e) CKD stage 3 to 4 <br/ >Note that the proportion of patients randomized without a confirmed SARS-CoV-2â??positive test will be closely monitored, and may be capped if it becomes greater than anticipated

Inclusion Criteria <br/ >For inclusion in the study patients should fulfill the following criteria based on local regulations <br/ >1 Provision of informed consent prior to any study-specific procedures <br/ >2 Male or female patients aged 18 years on the day consent given <br/ >3 Currently hospitalized <br/ >4 Hospital admission no more than 4 days prior to screening <br/ >5 Confirmed SARS-CoV-2 infection by laboratory testing within 10 days prior to screening, or strongly suspected SARS-CoV-2 infection on presentation <br/ >6 Chest radiography or CT findings that, in the opinion of the investigator are consistent with COVID-19 <br/ >7 Mild-moderate disease SpO2 94 with low-flow supplemental oxygen (5 liters or less) <br/ >8 Medical history of at least one of the following <br/ >(a) hypertension <br/ >(b) T2DM <br/ >(c) atherosclerotic cardiovascular disease <br/ >(d) heart failure (with either reduced or preserved LVEF) <br/ >(e) CKD stage 3 to 4 <br/ >Note that the proportion of patients randomized without a confirmed SARS-CoV-2â??positive test will be closely monitored, and may be capped if it becomes greater than anticipated

Inclusion Criteria <br/ >For inclusion in the study patients should fulfill the following criteria based on local regulations <br/ >1 Provision of informed consent prior to any study-specific procedures <br/ >2 Male or female patients aged 18 years on the day consent given <br/ >3 Currently hospitalized <br/ >4 Hospital admission no more than 4 days prior to screening <br/ >5 Confirmed SARS-CoV-2 infection by laboratory testing within 10 days prior to screening, or strongly suspected SARS-CoV-2 infection on presentation <br/ >6 Chest radiography or CT findings that, in the opinion of the investigator are consistent with COVID-19 <br/ >7 Mild-moderate disease SpO2 94 with low-flow supplemental oxygen (5 liters or less) <br/ >8 Medical history of at least one of the following <br/ >(a) hypertension <br/ >(b) T2DM <br/ >(c) atherosclerotic cardiovascular disease <br/ >(d) heart failure (with either reduced or preserved LVEF) <br/ >(e) CKD stage 3 to 4 <br/ >Note that the proportion of patients randomized without a confirmed SARS-CoV-2â??positive test will be closely monitored, and may be capped if it becomes greater than anticipated

Inclusion Criteria <br/ >For inclusion in the study patients should fulfill the following criteria based on local regulations <br/ >1 Provision of informed consent prior to any study-specific procedures <br/ >2 Male or female patients aged 18 years on the day consent given <br/ >3 Currently hospitalized <br/ >4 Hospital admission no more than 4 days prior to screening <br/ >5 Confirmed SARS-CoV-2 infection by laboratory testing within 10 days prior to screening, or strongly suspected SARS-CoV-2 infection on presentation <br/ >6 Chest radiography or CT findings that, in the opinion of the investigator are consistent with COVID-19 <br/ >7 Mild-moderate disease SpO2 94 with low-flow supplemental oxygen (5 liters or less) <br/ >8 Medical history of at least one of the following <br/ >(a) hypertension <br/ >(b) T2DM <br/ >(c) atherosclerotic cardiovascular disease <br/ >(d) heart failure (with either reduced or preserved LVEF) <br/ >(e) CKD stage 3 to 4 <br/ >Note that the proportion of patients randomized without a confirmed SARS-CoV-2â??positive test will be closely monitored, and may be capped if it becomes greater than anticipated